China Advances Comprehensive Pharmaceutical IP Protection with New Regulatory Frameworks

China’s pharmaceutical industry is undergoing a significant transformation, shifting from a dominant generic drug producer to a leader in innovative drug development. In 2025, the country approved 76 Class 1 innovative drugs, marking a 58.3% increase year-on-year and reaching a record high. Concurrently, nearly 3,000 new drug clinical trials were registered, accompanied by steady growth in research and development (R&D) investment. Cross-border licensing-out deals surged to 157, valued at $135.6 billion, representing a substantial share of global pharmaceutical transactions.

This dynamic growth is underpinned by a comprehensive intellectual property (IP) protection framework established through revisions to China’s Patent Law and Drug Administration Law. The framework encompasses five key pillars: regulatory data protection, patent term extension, patent linkage, judicial protection, and administrative enforcement. Together, these elements provide robust institutional support for pharmaceutical innovation.

The Measures for the Implementation of Drug Regulatory Data Protection, effective from May 15, 2026, grant exclusive protection periods of six, four, or three years for undisclosed pharmaceutical data, including non-clinical and clinical trial information. During these protection terms, generic drug applications relying on the protected data are barred from approval, with submissions permitted only one year prior to expiration. As of July 18, 2026, 54 drugs have secured data protection rights—19 with six-year terms and 31 with four-year terms—effectively bridging gaps left by patent protections and stabilizing long-term investment expectations for pharmaceutical enterprises.

The patent term extension system, introduced under the 2021 Patent Law, allows for a maximum extension of five years to compensate for time lost during drug approval processes. This mechanism addresses challenges posed by lengthy R&D cycles and shortened effective patent durations, mitigating investment risks for innovative drug developers. By mid-2026, 32 drugs—including chemical entities, biologics, and traditional Chinese medicines (TCMs)—had obtained patent term extensions, with 24 receiving the full five-year extension, thereby securing legitimate returns on innovation.

China’s patent linkage system, facilitated by the National Registered Drug Patent Information Platform, plays a critical role in resolving patent disputes during generic drug reviews. The platform, as of July 18, 2026, hosts 434 TCM entries, 1,296 chemical drug entries, 366 biological product entries, and 20,881 patent declarations. Disputes arising from patent linkage are addressed through both administrative adjudication and judicial litigation, balancing incentives for innovation with the accessibility of generic medicines.

By the end of 2025, the China National Intellectual Property Administration (CNIPA) had accepted approximately 270 administrative patent linkage cases, while the Intellectual Property Tribunal of the Supreme People’s Court handled 41 appellate cases related to patent linkage. The majority of these disputes concluded through reconciliation, effectively reducing the incidence of large-scale infringement litigation post-launch.

Established on January 1, 2019, the Intellectual Property Tribunal of the Supreme People’s Court centralizes appellate hearings on technical IP and monopoly cases nationwide. This centralization eliminates inconsistent rulings and local protectionism. The tribunal’s second-instance cases exhibit a reversal rate of 20.9% and a mediation-withdrawal rate of 37.7%, outperforming the national average for civil second-instance cases in higher courts. Punitive damages have been awarded in 58 cases, averaging over RMB 35 million per case; 73 cases with damages exceeding RMB 10 million averaged nearly RMB 72 million. The Supreme People’s Court has also published 14 landmark pharmaceutical patent cases clarifying legal standards on crystal patents, supplementary experimental data, and generic drug infringement determinations.

Local patent administrations actively conduct special enforcement campaigns targeting patent infringement and counterfeiting involving active pharmaceutical ingredients, formulations, and TCMs. High-profile cases concerning active pharmaceutical ingredient infringement receive focused supervision. Regular publication of typical enforcement cases standardizes infringement comparisons and evidence collection practices.

Administrative enforcement mechanisms provide expedited rights protection with reduced costs, creating a coordinated protection chain that integrates rapid administrative mediation, judicial oversight, and confirmation examinations. This system continuously regulates competition within China’s pharmaceutical market.

Through regulatory data protection, patent term extension, pre-market patent dispute resolution via patent linkage, targeted judicial rulings, and efficient administrative enforcement, China has constructed a full-life-cycle closed-loop pharmaceutical IP protection system. This system balances the need to incentivize original innovation with ensuring public access to medicines.

As supporting regulations continue to improve, China’s pharmaceutical IP protection framework is transitioning from institutional establishment to delivering tangible effects. This evolution is driving high-quality biomedical innovation and laying a solid foundation for China’s ambition to become a global pharmaceutical powerhouse.